Top Global Pharma Daiichi Sankyo Extends Use of the Medidata Clinical Cloud to China Leading Pharma Looks to Medidata Solutions to Bring Operational Efficiencies to Clinical Trials in China Business Wire NEW YORK -- July 31, 2013 Daiichi Sankyo Co., Ltd., a top 20 pharmaceutical company headquartered in Japan, is expanding its use of Medidata Solutions’ (NASDAQ: MDSO) cloud-based platform to support clinical trials conducted by its division in China. A long-time Medidata customer, Daiichi Sankyo will bring Medidata’s industry-leading applications for electronic data capture (EDC) and clinical data management (CDM) and randomization and trial supply management (RTSM) to its expanding clinical work in China. Daiichi Sankyo’s investment in the Medidata Clinical Cloud™ for its China division is expected to streamline trial activities, improve the efficiency of data capture and increase the productivity of site users and clinical monitors. By adopting Medidata’s industry-leading data capture, management and reporting solution (Medidata Rave^®) in conjunction with its agile randomization and trial supply management solution (Medidata Balance^®), Daiichi Sankyo will have access to a single cloud-based platform that provides a unified environment in which site staff will conduct patient randomization, supply dispensing and clinical data capture, as well as enabling collaboration and insightful metrics visibility for the whole research team. Daiichi Sankyo chose the Medidata platform for its expansion in China based on the improvements realized from its large-scale use of the Medidata platform since 2005. Medidata Services Partner Tigermed, a leading contract research organization (CRO), was involved in the selection and implementation of the Medidata platform for the China-based work. “Medidata and Daiichi Sankyo have a long and fruitful relationship as collaborators, and we are delighted they have asked us to provide the efficient, effective and modern infrastructure needed for their clinical development programs in China,” said Glen de Vries, president, Medidata Solutions. “Organizations like Daiichi Sankyo that leverage innovative clinical technologies will be the leaders in bringing new life-enhancing treatments to market.” Connect with Medidata: *Tweet this: With success in Japanese trials, Daiichi Sankyo extends use of Medidata Clinical Cloud to #China trials http://bit.ly/13wCHfE *Read our blog, Geeks Talk Clinical *Follow us on Twitter: @Medidata *Find us on LinkedIn About Medidata Solutions Medidata Solutions is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud™ brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of our global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations. Contact: Medidata Solutions Gail Janowitz, 212-918-1792 firstname.lastname@example.org
Top Global Pharma Daiichi Sankyo Extends Use of the Medidata Clinical Cloud to China
Press spacebar to pause and continue. Press esc to stop.